CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 


Royalty Pharma Plc's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Royalty Pharma Plc's ROA in the fourth quarter of 2023?
Royalty Pharma Plc achieved a return on average assets (ROA) of 58.61 % in its fourth quarter of 2023, this is above RPRX's average return on assets of -50.97%.
Royalty Pharma Plcs assets during the 12 months ending in the fourth quarter of 2023 are valued at $2 billion

ROA has improved compared to 11.72% in the third quarter of 2023, due to net income growth.

However, within the Healthcare sector 41 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2023 quarter, so far to 430, from total ROA ranking in the third quarter of 2023 at 1787.

What is ROA?


Return On Assets (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Total Assets Change -34.74 % -20.54 % -7.49 % -9.13 % -9.08 %
Y / Y Net Income Change - -44.61 % -28.53 % 297.47 % -
Net Income (TTM) in million 1,700 372 471 611 230
Return On Assets (TTM) 58.61 % 11.72 % 14.1 % 17.89 % 6.58 %
RPRX's Total Ranking # 430 # 1787 # 1706 # 1561 # 2517
Total Assets (TTM) in million 2,094 2,482 3,713 3,312 3,209
Seq. Total Assets Change -15.63 % -33.15 % 12.1 % 3.22 % 2.73 %
Seq. Net Income Change 487.81 % -65.25 % -30.99 % - -



Return On Assets Company Ranking
Within: No.
Industry # 14
Sector # 42
Overall # 428

Return On Assets Statistics
High Average Low
15.43 %
-50.97 %
-230.49 %
(Sep 30 2020)   (Sep 30 2017)





Financial Statements
Royalty Pharma Plc's Assets $ 2,094 million RPRX's Balance sheet
Royalty Pharma Plc's Income $ 718 million Quarterly RPRX's Income Statement
RPRX's Income by Division See RPRX's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
(Dec 31 2020)
FY 2020
(Dec 31 2016)
FY 2016
Y / Y Total Assets Change -34.74 % -9.08 % 5.16 % 38227.68 % -59.24 %
Total Assets in million 2,094 3,209 3,530 3,356 9
Y / Y Net Income Change 638.96 % -81.46 % -27.07 % - -
Net Income in million 1,700 230 1,241 1,702 -17
Return On Assets 81.18 % 7.17 % 35.16 % 50.71 % -197.25 %




Comment on RPRX's ROA in the fiscal year ending 2023
In the fiscal year 2023 ROA improved to 81.18 % compared to prior year, due to annual net income growth of 638.96 % to $1,700.09 million, and due to decline of value in Royalty Pharma Plc's assets by -34.74 % to $2,094.29 million, compared to $2,094.29 a year before.


More Return On Assets Ratios
RPRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RPRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Roa for RPRX's Competitors
Roa for Royalty Pharma Plc's Suppliers
Return On Assets for RPRX's Customers

You may also want to know
RPRX's Roi RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons
RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector ROA
Roivant Sciences Ltd   125.22 %
Entera Bio Ltd   83.90 %
Profound Medical Corp   65.06 %
Voyager Therapeutics Inc   40.79 %
Siga Technologies Inc  36.64 %
Star Equity Holdings Inc   34.46 %
Enzo Biochem Inc  32.62 %
Mimedx Group Inc   30.15 %
Idexx Laboratories Inc  28.11 %
Elite Pharmaceuticals Inc   27.42 %
Semler Scientific Inc   27.15 %
Alpha Tau Medical Ltd   27.15 %
Virios Therapeutics Inc   25.72 %
National Research Corporation  24.27 %
Mettler toledo International Inc   23.50 %
Inmode Ltd   22.93 %
Lantheus Holdings Inc   22.30 %
Johnson and Johnson  19.49 %
Medpace Holdings Inc   19.02 %
Earth Science Tech Inc   18.41 %
Corcept Therapeutics Inc  17.90 %
Chemed Corporation  17.68 %
Cardiff Lexington Corporation  17.40 %
Vertex Pharmaceuticals Inc  17.28 %
Harmony Biosciences Holdings inc   16.82 %
Zoetis Inc   16.75 %
Catalyst Pharmaceuticals Inc   16.47 %
West Pharmaceutical Services Inc   15.85 %
Halozyme Therapeutics Inc   15.78 %
Edwards Lifesciences Corporation  15.38 %


Date modified: 2024-02-15T15:42:59+00:00


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com